LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) Stock Price, Financials & Summary

Price chart

Jun 23Jun 26Jul 1Jul 7Jul 10Jul 20Jul 23Jul 28

Key dataJul 28, 2026

Open$4.38

From 52W high−10.32%

Volume366100.00

Market cap$89.28M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataJul 28, 2026

Open

$4.38

From 52W high

−10.32%

Volume

366100.00

Market cap

$89.28M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−12.0x

P/E (TTM)

—

RSI (14)

33.6

MomentumView details →

1D Return

−6.00%

YTD Return

+12.72%

SummaryUpdated Mar 1, 2026

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) is a clinical-stage drug discovery company founded in 2005 and based in Pasadena, California. The company went public in 2007 and specializes in developing novel therapeutic compounds targeting protein phosphatases, a class of enzymes involved in cellular regulation. Lixte focuses on creating treatments for serious diseases including various cancers, vascular diseases, metabolic disorders, and rare hereditary conditions through its proprietary biomarker technology platform.

Ask drillr about LIXTE BIOTECHNOLOGY HOLDINGS, INC. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−12.0x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

11.2x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−91.55%

ROA (TTM)

−66.95%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+22.07%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+20.75%

EBITDA YoY

—

MomentumView details →

1D Return

−6.00%

YTD Return

+12.72%

1Y Return

+15.67%

RSI (14)

33.6

vs 50D SMA

−29.33%

vs 200D SMA

+2.22%

Capital & dividendView details →

Debt/Equity

0.13x

Current Ratio

2.78x

Quick Ratio

2.78x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.18

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−7.27M

Op. CF (TTM)

−4.33M

Latest newsMore news →

NOMAD Power Solutions adjourned its reconvened Special Meeting of Stockholders on October 2, 2026 without conducting any business, with the meeting to reconvene on October 30, 2026.17d ago

Nomad Power Solutions, Inc. issued a $6.57 million secured promissory note to Streeterville Capital, LLC for gross proceeds of $6.0 million, with a 9% annual interest rate and 12-month maturity.19d ago

Similar companies

Atara Biotherapeutics, Inc.ATRA Neumora Therapeutics, Inc. Common StockNMRA Anixa Biosciences, Inc.ANIX OnKure Therapeutics, Inc.OKUR Milestone Pharmaceuticals Inc.MIST Cellectis S.A.CLLS Find similar companies →

Latest newsMore news →

NOMAD Power Solutions adjourned its reconvened Special Meeting of Stockholders on October 2, 2026 without conducting any business, with the meeting to reconvene on October 30, 2026.17d ago Nomad Power Solutions, Inc. issued a $6.57 million secured promissory note to Streeterville Capital, LLC for gross proceeds of $6.0 million, with a 9% annual interest rate and 12-month maturity.19d ago LIXTE Biotechnology Holdings completed its corporate name change to NOMAD Power Solutions, Inc.106d ago